Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Life360 Innovations

Request full access

Medical Device Manufacturing Company Canada | Life360 Innovations Inc.

Vancouver, CanadaFounded 2010Health Tech & Medtech

About Life360 Innovations

Life360 Innovations Inc. is a Canadian medical device company focused on creating solutions for the urology sector, specifically for male urinary incontinence (UI).

The company was co-founded in 2010 by Robert Orr, the current President & CEO, and his father, Russ Orr. The inspiration for the company came from Ken Kunz, who, after successful prostate cancer surgery, developed UI and subsequently invented a personal device to manage his condition. This prototype became the foundation for the company's flagship product. Robert Orr, leveraging his background as a finance professional, transitioned to a full-time entrepreneur to commercialize Ken's invention, a journey he describes as more challenging and rewarding than anticipated. The company began by securing its first U.S. patent and collaborating with the MAKE+ Group at the British Columbia Institute of Technology to transform the prototype into a licensed medical device.

The core of Life360 Innovations' business is the manufacturing and distribution of the Contino®, a non-surgical, self-managed medical device for male bladder leakage. This product is designed to be a discreet solution that allows users to manage UI without resorting to absorbent pads or collection devices. The business operates in the multi-billion dollar urinary incontinence market, which affects an estimated 420 million adults worldwide. The company's business model involves distributing its Health Canada-licensed devices through a proprietary network of medical professional partners, initially focusing on the Canadian market with plans for global expansion. Life360 Innovations has established an ISO 13485:2016 compliant quality management system, meeting Canadian, EU, and US regulations, and has raised $15.2M in funding from investors including Supernode, WUTIF Capital, and VentureLabs.

The company's primary product, Contino®, is a novel, externally worn device that controls urine flow, offering men an alternative to traditional incontinence products. It aims to provide protection and independence. Looking forward, Life360 Innovations intends to leverage its established infrastructure to develop and manufacture other health-focused products. Their pipeline includes a female version of the Contino® and a device for fecal incontinence.

Source: Dealroom company data

Life360 Innovations in the Vancouver ecosystem

Live from Dealroom

The Life360 Innovations office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Supernode
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇦 Canada100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Life360 Innovations on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Life360 Innovations on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.